Lupin Limited on Friday (July 4) announced the launch of ipratropium bromide nasal solution (nasal spray) in two strengths in the United States. The product is a bioequivalent of Atrovent nasal spray, marketed by Boehringer Ingelheim Pharmaceuticals, Inc.Ipratropium bromide nasal solution 0.03% is indicated for the symptomatic relief of rhinorrhoea associated with allergic and nonallergic perennial rhinitis in adults and children aged six years and older. The same in 0.06% strength is indicated for the symptomatic relief of rhinorrhoea associated with the common cold or seasonal allergic rhinitis for adults and children aged five years and older.
According to IQVIA MAT data for May 2025, ipratropium bromide nasal solution (RLD Atrovent) recorded estimated annual sales of $63 million in the US.
Also Read: Lupin gets FDA nod for post-eye surgery medication loteprednol etabonate ophthalmic gel
Lupin had earlier in the week also announced the creation of a wholly owned subsidiary, LupinLife Consumer Healthcare, effective July 1, 2025. The move is intended to sharpen the company’s focus on the self-care and over-the-counter (OTC) wellness segment.The new entity will manage Lupin’s consumer healthcare portfolio, which includes OTC brands such as Softovac, Beplex Forte, Corcium, and Aptivate. The company said the move will enable targeted investments, support market expansion, and drive faster growth in the consumer health segment.Anil V. Kaushal has been appointed Chief Executive Officer of LupinLife Consumer Healthcare. The company stated that the dedicated unit will operate with greater agility and a sharper focus on innovation and consumer access.Shares of Lupin Ltd closed at ₹1,982.20, up ₹26.60 or 1.36%, on the BSE.Also Read: Lupin shares gain ahead of US drug launch that can fetch $200 million in FY26
